Molina Healthcare, Inc. (MOH) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $192.18 (-1.23%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 20, 2026 | Stephen Baxter | Wells Fargo | $141.00 | -26.6% |
| Feb 10, 2026 | Andrew Mok | Barclays | $133.00 | -30.8% |
| Jan 9, 2026 | Ann Hynes | Mizuho Securities | $220.00 | +14.5% |
| Jan 7, 2026 | Stephen Baxter | Wells Fargo | $208.00 | +8.2% |
| Oct 24, 2025 | Erin Wright | Morgan Stanley | $158.00 | -17.8% |
| Oct 24, 2025 | Scott Fidel | Goldman Sachs | $167.00 | -13.1% |
| Oct 14, 2025 | Scott Fidel | Goldman Sachs | $207.00 | +7.7% |
| Jul 11, 2025 | Ann Hynes | Mizuho Securities | $330.00 | +71.7% |
| Jul 10, 2025 | Erin Wright | Morgan Stanley | $266.00 | +38.4% |
| Jun 9, 2025 | Erin Wright | Morgan Stanley | $364.00 | +89.4% |
| Apr 15, 2025 | Michael Ha | Robert W. Baird | $375.00 | +95.1% |
| Oct 24, 2024 | Michael Ha | Robert W. Baird | $331.00 | +72.2% |
| Aug 5, 2024 | Stephen Baxter | Wells Fargo | $360.00 | +87.3% |
| Jul 24, 2024 | David Windley | Jefferies | $297.00 | +54.5% |
| Jul 15, 2024 | David MacDonald | Truist Financial | $400.00 | +108.1% |
| May 29, 2024 | Michael Ha | Robert W. Baird | $405.00 | +110.7% |
| Apr 25, 2024 | Andrew Mok | Barclays | $430.00 | +123.7% |
| Apr 15, 2024 | Stephen Baxter | Wells Fargo | $410.00 | +113.3% |
| Feb 15, 2024 | Stephen Baxter | Wells Fargo | $420.00 | +118.5% |
| Oct 29, 2021 | Steven Valiquette | Barclays | $340.00 | +76.9% |
Top Analysts Covering MOH
MOH vs Sector & Market
| Metric | MOH | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 3.00 | 2.24 | 2.41 |
| Analyst Count | 17 | 8 | 18 |
| Target Upside | -13.6% | +1150.3% | +14.9% |
| P/E Ratio | 22.50 | 6.85 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $42.44B | $44.21B | $44.75B | 11 |
| 2027-03-31 | $11.04B | $11.25B | $11.50B | 2 |
| 2027-06-30 | $11.22B | $11.43B | $11.69B | 2 |
| 2027-09-30 | $11.44B | $11.66B | $11.92B | 2 |
| 2027-12-31 | $11.58B | $11.80B | $12.06B | 2 |
| 2028-03-31 | $11.31B | $11.52B | $11.78B | 1 |
| 2028-06-30 | $11.66B | $11.88B | $12.15B | 1 |
| 2028-09-30 | $11.90B | $12.12B | $12.39B | 1 |
| 2028-12-31 | $12.14B | $12.37B | $12.65B | 1 |
| 2029-12-31 | $47.64B | $49.94B | $52.34B | 7 |
| 2030-12-31 | $50.32B | $52.76B | $55.30B | 7 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $5.05 | $5.09 | $5.17 | 11 |
| 2027-03-31 | $2.82 | $2.89 | $2.97 | 2 |
| 2027-06-30 | $2.35 | $2.41 | $2.48 | 1 |
| 2027-09-30 | $2.29 | $2.35 | $2.42 | 1 |
| 2027-12-31 | $1.35 | $1.39 | $1.43 | 2 |
| 2028-03-31 | $3.50 | $3.58 | $3.68 | 3 |
| 2028-06-30 | $2.93 | $3.00 | $3.09 | 2 |
| 2028-09-30 | $3.07 | $3.15 | $3.24 | 2 |
| 2028-12-31 | $1.93 | $1.97 | $2.03 | 3 |
| 2029-12-31 | $16.28 | $17.32 | $18.40 | 2 |
| 2030-12-31 | $23.86 | $25.38 | $26.97 | 2 |
Frequently Asked Questions
What is the analyst consensus for MOH?
The consensus among 17 analysts covering Molina Healthcare, Inc. (MOH) is Hold with an average price target of $175.64.
What is the highest price target for MOH?
The highest price target for MOH is $430.00, set by Andrew Mok at Barclays on 2024-04-25.
What is the lowest price target for MOH?
The lowest price target for MOH is $133.00, set by Andrew Mok at Barclays on 2026-02-10.
How many analysts cover MOH?
17 analysts have issued ratings for Molina Healthcare, Inc. in the past 12 months.
Is MOH a buy or sell right now?
Based on 17 analyst ratings, MOH has a consensus rating of Hold (3.00/5) with a -13.6% upside to the consensus target of $175.64.
What are the earnings estimates for MOH?
Analysts estimate MOH will report EPS of $5.09 for the period ending 2026-12-31, with revenue estimated at $44.21B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.